» Articles » PMID: 16392812

Structure-activity Relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides As Highly Potent and Selective Agonists at the Human A3 Adenosine Receptor

Overview
Journal J Med Chem
Specialty Chemistry
Date 2006 Jan 6
PMID 16392812
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

We have established structure-activity relationships of novel 4'-thionucleoside analogues as the A(3) adenosine receptor (AR) agonists. Binding affinity, selectivity toward other AR subtypes, and efficacy in inhibition of adenylate cyclase were studied. From this study, 2-chloro-N(6)-methyl-4'-thioadenosine-5'-methyluronamide (36a) emerged as the most potent and selective agonist at the human A(3) AR. We have also revealed that, similar to 4'-oxoadenosine analogues, at least one hydrogen on the 5'-uronamide moiety was necessary for high-affinity binding at the human A(3) AR, presumably to allow this group to donate a H bond within the binding site. Furthermore, bulky substituents on the 5'-uronamide reduced binding affinity, but in some cases large 5'-uronamide substituents, such as substituted benzyl and 2-phenylethyl groups, maintained moderate affinity with reduced efficacy, leading to A(3) AR partial agonists or antagonists. In several cases for which the corresponding 4'-oxonucleosides have been studied, the 4'-thionucleosides showed higher binding affinity to the A(3) AR.

Citing Articles

Structure-Activity Relationship of Truncated 4'-Selenonucleosides: A Adenosine Receptor Activity and Binding Selectivity.

Kim M, Choi H, Nayak A, Tripathi S, Aswar V, Gaikwad V ACS Med Chem Lett. 2024; 15(9):1620-1626.

PMID: 39420956 PMC: 11482266. DOI: 10.1021/acsmedchemlett.4c00344.


Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A/A Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.

Kim G, Hou X, Byun W, Kim G, Jarhad D, Lee G J Med Chem. 2023; 66(17):12249-12265.

PMID: 37603705 PMC: 10896643. DOI: 10.1021/acs.jmedchem.3c00806.


NUCLEOSIDE PRODRUGS OF A ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS.

Besada P, Mamedova L, Palaniappan K, Gao Z, Joshi B, Jeong L Collect Czechoslov Chem Commun. 2021; 71(6):912-928.

PMID: 34815583 PMC: 8608517. DOI: 10.1135/cccc20060912.


Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.

Lee Y, Hou X, Lee J, Nayak A, Alexander V, Sharma P J Med Chem. 2021; 64(17):12525-12536.

PMID: 34435786 PMC: 8840841. DOI: 10.1021/acs.jmedchem.1c00239.


Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato R Adv Drug Deliv Rev. 2021; 176:113888.

PMID: 34314787 PMC: 8440458. DOI: 10.1016/j.addr.2021.113888.